Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Psychiatry
•
Public & Community Psychiatry
•
General Outpatient Psychiatry
•
Psychotic Disorders
•
Psychopharmacology
When do you consider the use of lumateperone to treat schizophrenia spectrum disorders?
Related Questions
How would you decide between escalation to clozapine vs xanomeline-tropsium (Cobenfy) for treatment-resistant schizophrenia?
Which patients do you think would benefit most from xanomeline-tropsium (Cobenfy) monotherapy?
What strategies have you found effective for obtaining insurance approval for xanomeline-tropsium (Cobenfy)?
When do you consider using olanzapine/samidorphan?
What opportunities do you see for combining xanomeline-tropsium (Cobenfy) with other anti-psychotic agents?
When do you consider using Uzedy, the subcutaneous long-acting injectable version of risperidone?
When, if ever, do you consider prescribing clozapine after only one unsuccessful antipsychotic trial in schizophrenia?
How do you approach deprescribing anticholinergics in patients with psychotic disorders?
How have you incorporated long-acting injectables into private practice or other settings that haven’t traditionally offered them?
What is your approach to handling negative cognitive side effects of atypical/typical antipsychotics?
